Presidents Pick

True to the vision of OTS, we have worked with Liebert through our BOD Committees to compile a list of important open-access NAT publications relating to the development of safe oligonucleotides. Finding high-quality publications to guide researchers and developers of oligonucleotide therapeutics can be ...

The OTS Annual Meeting 2023 in Barcelona was a showcase of excellent science and a demonstration of how far our field has advanced over the past nineteen years. Congratulations to our LAA winners Dr. Sudhir Agrawal and Dr. Cy Stein, our other award winners, our ...

During the 2022 OTS annual meeting in Phoenix it was easy to listen to the talks announcing successful clinical trial results and assume that obviously favorable data were becoming routine. Willeke van Roon-Mom, Chantal Ferguson, and Annemieke Aartsma-Rus have just published a commentary (Nucleic ...

Researchers involved in developing oligonucleotide therapeutics have always been known for picking difficult problems related to difficult diseases. SOD1-ALS is a deadly neurodegenerative disease caused by a mutation in the SOD1 protein. Because the disease is due to the SOD1 mutation, it is possible to ...

PMID: 36881759 DOI: 10.1093/nar/gkad067 Writing a good review article is not easy. A good Review not only summarizes the literature, it also provides an expert perspective so that the reader has enough insight to sort the important from the unimportant. That means that the expert authors, who ...

The journal RNA, the official publication of the RNA society, has always been one of my favorite journals. RNA’s April issue is devoted to Perspective articles related to nucleic acids therapeutics. Michelle Hastings and Adrian Krainer deserve our thanks as they took on the task ...

I would like to thank everyone who attended OTS 2022, whether in person or virtual. Special thanks to Keith Gagnon and Annemieke Aartsma-Rus and the entire organizing group for putting together such a great schedule of talks. Masad Damha coordinated the intricate network of award ...

Today’s President’s pick is a bit unusual. I was watching television and noticed a new commercial. A jolly man was happily proclaiming that he had a new medication for controlling his high cholesterol. He seemed very pleased. We’ve all seen these commercials many times before, ...

By: David Corey Establishing an environment in which rigorous scientific inquiry is practiced: A personal journey. Stanley Crooke Nucleic Acids Research, gkac526, https://doi.org/10.1093/nar/gkac526 Published: 08 July 2022. https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkac526/6633881?login=true The Story of Ionis Pharmaceuticals For those new to the field, Ionis Pharmaceuticals has always been ...

Successful nucleic acid therapeutic projects have one thing in common - rigor. Lack of controls has many consequences ranging from failed companies, seminars that waste the time of all involved, and lost hopes of patients. In this “President’s Pick”, Past President Annemieke Aartsma-Rus lays ...